����JFIFXX�����    $.' ",#(7),01444'9=82<.342  2!!22222222222222222222222222222222222222222222222222����"��4�� ���,�PG"Z_�4�˷����kjز�Z�,F+��_z�,�© �����zh6�٨�ic�fu���#ډb���_�N�?��wQ���5-�~�I���8����TK<5o�Iv-�����k�_U_�����~b�M��d����Ӝ�U�Hh��?]��E�w��Q���k�{��_}qFW7HTՑ��Y��F�?_�'ϔ��_�Ջt��=||I ��6�έ"�����D���/[�k�9���Y�8ds|\���Ҿp6�Ҵ���]��.����6�z<�v��@]�i%��$j��~�g��J>��no����pM[me�i$[����s�o�ᘨ�˸ nɜG-�ĨU�ycP�3.DB�li�;��hj���x7Z^�N�h������N3u{�:j�x�힞��#M&��jL P@_���� P��&��o8������9�����@Sz6�t7#O�ߋ �s}Yf�T���lmr����Z)'N��k�۞p����w\�Tȯ?�8`�O��i{wﭹW�[�r�� ��Q4F�׊���3m&L�=��h3����z~��#�\�l :�F,j@�� ʱ�wQT����8�"kJO���6�֚l����}���R�>ډK���]��y����&����p�}b��;N�1�m�r$�|��7�>e�@B�TM*-iH��g�D�)� E�m�|�ؘbҗ�a��Ҿ����t4���o���G��*oCN�rP���Q��@z,|?W[0�����:�n,jWiE��W��$~/�hp\��?��{(�0���+�Y8rΟ�+����>S-S����VN;�}�s?.����� w�9��˟<���Mq4�Wv'��{)0�1mB��V����W[�����8�/<� �%���wT^�5���b��)iM� pg�N�&ݝ��VO~�q���u���9� ����!��J27����$O-���! �:�%H��� ـ����y�ΠM=t{!S�� oK8������t<����è:a������[�����ա�H���~��w��Qz`�po�^ ����Q��n� �,uu�C�$ ^���,������8�#��:�6��e�|~���!�3�3.�\0��q��o�4`.|� ����y�Q�`~;�d�ׯ,��O�Zw�������`73�v�܋�<���Ȏ�� ـ4k��5�K�a�u�=9Yd��$>x�A�&�� j0� ���vF��� Y�|�y��� ~�6�@c��1vOp�Ig����4��l�OD���L����� R���c���j�_�uX6��3?nk��Wy�f;^*B� ��@�~a�`��Eu������+���6�L��.ü>��}y���}_�O�6�͐�:�YrG�X��kG�����l^w���~㒶sy��Iu�!� W ��X��N�7BV��O��!X�2����wvG�R�f�T#�����t�/?���%8�^�W�aT��G�cL�M���I��(J����1~�8�?aT ���]����AS�E��(��*E}� 2��#I/�׍qz��^t�̔���b�Yz4x���t�){ OH��+(E��A&�N�������XT��o��"�XC��'���)}�J�z�p� ��~5�}�^����+�6����w��c��Q�|Lp�d�H��}�(�.|����k��c4^�"�����Z?ȕ ��a<�L�!039C� �Eu�C�F�Ew�ç ;�n?�*o���B�8�bʝ���'#Rqf���M}7����]����s2tcS{�\icTx;�\��7K���P���ʇ Z O-��~��c>"��?�������P��E��O�8��@�8��G��Q�g�a�Վ���󁶠�䧘��_%#r�>�1�z�a��eb��qcPѵ��n���#L��� =��׀t� L�7�`��V���A{�C:�g���e@�w1 Xp3�c3�ġ����p��M"'-�@n4���fG��B3�DJ�8[Jo�ߐ���gK)ƛ��$���� ���8�3�����+���� �����6�ʻ���� ���S�kI�*KZlT _`���?��K����QK�d����B`�s}�>���`��*�>��,*@J�d�oF*����弝��O}�k��s��]��y�ߘ��c1G�V���<=�7��7����6�q�PT��tXԀ�!9*4�4Tހ3XΛex�46���Y��D ����� �BdemDa����\�_l,��G�/���֌7���Y�](�xTt^%�GE�����4�}bT���ڹ�����;Y)���B�Q��u��>J/J �⮶.�XԄ��j�ݳ�+E��d ��r�5�_D�1 ��o�� �B�x�΢�#���<��W�����8���R6�@g�M�.��� dr�D��>(otU��@x=��~v���2� ӣ�d�oBd��3�eO�6�㣷�����ݜ6��6Y��Qz`��S��{���\P�~z m5{J/L��1������<�e�ͅPu�b�]�ϔ���'������f�b� Zpw��c`"��i���BD@:)ִ�:�]��hv�E�w���T�l��P���"Ju�}��وV J��G6��. J/�Qgl߭�e�����@�z�Zev2u�)]կ�����7x���s�M�-<ɯ�c��r�v�����@��$�ޮ}lk���a���'����>x��O\�ZFu>�����ck#��&:��`�$�ai�>2Δ����l���oF[h��lE�ܺ�Πk:)���`�� $[6�����9�����kOw�\|���8}������ބ:��񶐕��I�A1/�=�2[�,�!��.}gN#�u����b��� ~��݊��}34q����d�E��Lc��$��"�[q�U�硬g^��%B �z���r�pJ�ru%v\h1Y�ne`ǥ:g���pQM~�^�Xi� ��`S�:V29.�P���V�?B�k�� AEvw%�_�9C�Q����wKekPؠ�\�;Io d�{ ߞo�c1eP����\� `����E=���@K<�Y���eڼ�J���w����{av�F�'�M�@/J��+9p���|]�����Iw &`��8���&M�hg��[�{��Xj��%��Ӓ�$��(����ʹN���<>�I���RY���K2�NPlL�ɀ)��&e����B+ь����( � �JTx���_?EZ� }@ 6�U���뙢ط�z��dWI�n` D����噥�[��uV��"�G&Ú����2g�}&m��?ċ�"����Om#��������� ��{�ON��"S�X��Ne��ysQ���@Fn��Vg���dX�~nj�]J�<�K]:��FW��b�������62�=��5f����JKw��bf�X�55��~J �%^����:�-�QIE��P��v�nZum� z � ~ə ���� ���ة����;�f��\v���g�8�1��f24;�V���ǔ�)����9���1\��c��v�/'Ƞ�w�������$�4�R-��t���� e�6�/�ġ �̕Ecy�J���u�B���<�W�ַ~�w[B1L۲�-JS΂�{���΃������A��20�c#��@ 0!1@AP"#2Q`$3V�%45a6�FRUq��� ����^7ׅ,$n�������+��F�`��2X'��0vM��p�L=������5��8������u�p~���.�`r�����\���O��,ư�0oS ��_�M�����l���4�kv\JSd���x���SW�<��Ae�IX����������$I���w�:S���y���›R��9�Q[���,�5�;�@]�%���u�@ *ro�lbI �� ��+���%m:�͇ZV�����u�̉����θau<�fc�.����{�4Ա� �Q����*�Sm��8\ujqs]{kN���)qO�y�_*dJ�b�7���yQqI&9�ԌK!�M}�R�;������S�T���1���i[U�ɵz�]��U)V�S6���3$K{�ߊ<�(� E]Զ[ǼENg�����'�\?#)Dkf��J���o��v���'�%ƞ�&K�u�!��b�35LX�Ϸ��63$K�a�;�9>,R��W��3�3� d�JeTYE.Mϧ��-�o�j3+y��y^�c�������VO�9NV\nd�1 ��!͕_)a�v;����թ�M�lWR1��)El��P;��yوÏ�u 3�k�5Pr6<�⒲l�!˞*��u־�n�!�l:����UNW ��%��Chx8vL'��X�@��*��)���̮��ˍ��� ���D-M�+J�U�kvK����+�x8��cY������?�Ԡ��~3mo��|�u@[XeY�C�\Kp�x8�oC�C�&����N�~3-H���� ��MX�s�u<`���~"WL��$8ξ��3���a�)|:@�m�\���^�`�@ҷ)�5p+��6���p�%i)P M���ngc�����#0Aruz���RL+xSS?���ʮ}()#�t��mˇ!��0}}y����<�e� �-ή�Ԩ��X������ MF���ԙ~l L.3���}�V뽺�v�����멬��Nl�)�2����^�Iq��a��M��qG��T�����c3#������3U�Ǎ���}��לS�|qa��ڃ�+���-��2�f����/��bz��ڐ�� �ݼ[2�ç����k�X�2�* �Z�d���J�G����M*9W���s{��w���T��x��y,�in�O�v��]���n����P�$�JB@=4�OTI�n��e�22a\����q�d���%�$��(���:���: /*�K[PR�fr\nڙdN���F�n�$�4�[�� U�zƶ����� �mʋ���,�ao�u 3�z� �x��Kn����\[��VFmbE;�_U��&V�Gg�]L�۪&#n%�$ɯ�dG���D�TI=�%+AB�Ru#��b4�1�»x�cs�YzڙJG��f��Il��d�eF'T� iA��T���uC�$����Y��H?����[!G`}���ͪ� �纤Hv\������j�Ex�K���!���OiƸ�Yj�+u-<���'q����uN�*�r\��+�]���<�wOZ.fp�ێ��,-*)V?j-kÊ#�`�r��dV����(�ݽBk�����G�ƛk�QmUڗe��Z���f}|����8�8��a���i��3'J�����~G_�^���d�8w������ R�`(�~�.��u���l�s+g�bv���W���lGc}��u���afE~1�Ue������Z�0�8�=e�� f@/�jqEKQQ�J��oN��J���W5~M>$6�Lt�;$ʳ{���^��6�{����v6���ķܰg�V�cnn �~z�x�«�,2�u�?cE+Ș�H؎�%�Za�)���X>uW�Tz�Nyo����s���FQƤ��$��*�&�LLXL)�1�" L��eO��ɟ�9=���:t��Z���c��Ž���Y?�ӭV�wv�~,Y��r�ۗ�|�y��GaF�����C�����.�+� ���v1���fήJ�����]�S��T��B��n5sW}y�$��~z�'�c ��8 ��� ,! �p��VN�S��N�N�q��y8z˱�A��4��*��'������2n<�s���^ǧ˭P�Jޮɏ�U�G�L�J�*#��<�V��t7�8����TĜ>��i}K%,���)[��z�21z ?�N�i�n1?T�I�R#��m-�����������������1����lA�`��fT5+��ܐ�c�q՝��ʐ��,���3�f2U�եmab��#ŠdQ�y>\��)�SLY����w#��.���ʑ�f��� ,"+�w�~�N�'�c�O�3F�������N<���)j��&��,-� �љ���֊�_�zS���TǦ����w�>��?�������n��U仆�V���e�����0���$�C�d���rP �m�׈e�Xm�Vu� �L��.�bֹ��� �[Դaզ���*��\y�8�Է:�Ez\�0�Kq�C b��̘��cө���Q��=0Y��s�N��S.���3.���O�o:���#���v7�[#߫ ��5�܎�L���Er4���9n��COWlG�^��0k�%<���ZB���aB_���������'=��{i�v�l�$�uC���mƎҝ{�c㱼�y]���W�i ��ߧc��m�H� m�"�"�����;Y�ߝ�Z�Ǔ�����:S#��|}�y�,/k�Ld� TA�(�AI$+I3��;Y*���Z��}|��ӧO��d�v��..#:n��f>�>���ȶI�TX��� 8��y����"d�R�|�)0���=���n4��6ⲑ�+��r<�O�܂~zh�z����7ܓ�HH�Ga롏���nCo�>������a ���~]���R���̲c?�6(�q�;5%� |�uj�~z8R=X��I�V=�|{v�Gj\gc��q����z�؋%M�ߍ����1y��#��@f^���^�>N�����#x#۹��6�Y~�?�dfPO��{��P�4��V��u1E1J �*|���%���JN��`eWu�zk M6���q t[�� ��g�G���v��WIG��u_ft����5�j�"�Y�:T��ɐ���*�;� e5���4����q$C��2d�}���� _S�L#m�Yp��O�.�C�;��c����Hi#֩%+) �Ӎ��ƲV���SYź��g |���tj��3�8���r|���V��1#;.SQ�A[���S������#���`n�+���$��$I �P\[�@�s��(�ED�z���P��])8�G#��0B��[ى��X�II�q<��9�~[Z멜�Z�⊔IWU&A>�P~�#��dp<�?����7���c��'~���5 ��+$���lx@�M�dm��n<=e�dyX��?{�|Aef ,|n3�<~z�ƃ�uۧ�����P��Y,�ӥQ�*g�#먙R�\���;T��i,��[9Qi歉����c>]9�� ��"�c��P�� �Md?٥��If�ت�u��k��/����F��9�c*9��Ǎ:�ØF���z�n*�@|I�ށ9����N3{'��[�'ͬ�Ҳ4��#}��!�V� Fu��,�,mTIk���v C�7v���B�6k�T9��1�*l� '~��ƞF��lU��'�M ����][ΩũJ_�{�i�I�n��$���L�� j��O�dx�����kza۪��#�E��Cl����x˘�o�����V���ɞ�ljr��)�/,�߬h�L��#��^��L�ф�,íMƁe�̩�NB�L�����iL����q�}��(��q��6IçJ$�W�E$��:������=#����(�K�B����zђ <��K(�N�۫K�w��^O{!����)�H���>x�������lx�?>Պ�+�>�W���,Ly!_�D���Ō�l���Q�!�[ �S����J��1��Ɛ�Y}��b,+�Lo�x�ɓ)����=�y�oh�@�꥟/��I��ѭ=��P�y9��� �ۍYӘ�e+�p�Jnϱ?V\SO%�(�t� ���=?MR�[Ș�����d�/ ��n�l��B�7j� ��!�;ӥ�/�[-���A�>�dN�sLj ��,ɪv��=1c�.SQ�O3�U���ƀ�ܽ�E����������̻��9G�ϷD�7(�}��Ävӌ\�y�_0[w ���<΍>����a_��[0+�L��F.�޺��f�>oN�T����q;���y\��bՃ��y�jH�<|q-eɏ�_?_9+P���Hp$�����[ux�K w�Mw��N�ی'$Y2�=��q���KB��P��~������Yul:�[<����F1�2�O���5=d����]Y�sw:���Ϯ���E��j,_Q��X��z`H1,#II ��d�wr��P˂@�ZJV����y$�\y�{}��^~���[:N����ߌ�U�������O��d�����ؾe��${p>G��3c���Ė�lʌ�� ת��[��`ϱ�-W����dg�I��ig2��� ��}s ��ؤ(%#sS@���~���3�X�nRG�~\jc3�v��ӍL��M[JB�T��s3}��j�Nʖ��W����;7��ç?=X�F=-�=����q�ߚ���#���='�c��7���ڑW�I(O+=:uxq�������������e2�zi+�kuG�R��������0�&e�n���iT^J����~\jy���p'dtG��s����O��3����9* �b#Ɋ�� p������[Bws�T�>d4�ۧs���nv�n���U���_�~,�v����ƜJ1��s�� �QIz��)�(lv8M���U=�;����56��G���s#�K���MP�=��LvyGd��}�VwWBF�'�à �?MH�U�g2�� ����!�p�7Q��j��ڴ����=��j�u��� Jn�A s���uM������e��Ɔ�Ҕ�!)'��8Ϣ�ٔ��ޝ(��Vp���צ֖d=�IC�J�Ǡ{q������kԭ�߸���i��@K����u�|�p=..�*+����x�����z[Aqġ#s2a�Ɗ���RR�)*HRsi�~�a &f��M��P����-K�L@��Z��Xy�'x�{}��Zm+���:�)�) IJ�-i�u���� ���ܒH��'�L(7�y�GӜq���� j��� 6ߌg1�g�o���,kر���tY�?W,���p���e���f�OQS��!K�۟cҒA�|ս�j�>��=⬒��˧L[�� �߿2JaB~R��u�:��Q�] �0H~���]�7��Ƽ�I���(}��cq '�ήET���q�?f�ab���ӥvr� �)o��-Q��_'����ᴎo��K������;��V���o��%���~OK ����*��b�f:���-ťIR��`B�5!RB@���ï�� �u �̯e\�_U�_������� g�ES��3�������QT��a����x����U<~�c?�*�#]�MW,[8O�a�x��]�1bC|踤�P��lw5V%�)�{t�<��d��5���0i�XSU��m:��Z�┵�i�"��1�^B�-��P�hJ��&)O��*�D��c�W��vM��)����}���P��ܗ-q����\mmζZ-l@�}��a��E�6��F�@��&Sg@���ݚ�M����� ȹ 4����#p�\H����dYDo�H���"��\��..R�B�H�z_�/5˘����6��KhJR��P�mƶi�m���3�,#c�co��q�a)*Pt����R�m�k�7x�D�E�\Y�閣_X�<���~�)���c[[�BP����6�Yq���S��0����%_����;��Àv�~�| VS؇ ��'O0��F0��\���U�-�d@�����7�SJ*z��3n��y��P����O���������m�~�P�3|Y��ʉr#�C�<�G~�.,! ���bqx���h~0=��!ǫ�jy����l�O,�[B��~��|9��ٱ����Xly�#�i�B��g%�S��������tˋ���e���ې��\[d�t)��.+u�|1 ������#�~Oj����hS�%��i.�~X���I�H�m��0n���c�1uE�q��cF�RF�o���7� �O�ꮧ� ���ۛ{��ʛi5�rw?׌#Qn�TW��~?y$��m\�\o����%W� ?=>S�N@�� �Ʈ���R����N�)�r"C�:��:����� �����#��qb��Y�. �6[��2K����2u�Ǧ�HYR��Q�MV��� �G�$��Q+.>�����nNH��q�^��� ����q��mM��V��D�+�-�#*�U�̒ ���p욳��u:�������IB���m���PV@O���r[b= �� ��1U�E��_Nm�yKbN�O���U�}�the�`�|6֮P>�\2�P�V���I�D�i�P�O;�9�r�mAHG�W�S]��J*�_�G��+kP�2����Ka�Z���H�'K�x�W�MZ%�O�YD�Rc+o��?�q��Ghm��d�S�oh�\�D�|:W������UA�Qc yT�q������~^�H��/��#p�CZ���T�I�1�ӏT����4��"�ČZ�����}��`w�#�*,ʹ�� ��0�i��課�Om�*�da��^gJ݅{���l�e9uF#T�ֲ��̲�ٞC"�q���ߍ ոޑ�o#�XZTp����@ o�8��(jd��xw�]�,f���`~�|,s��^����f�1���t��|��m�򸄭/ctr��5s��7�9Q�4�H1꠲BB@l9@���C�����+�wp�xu�£Yc�9��?`@#�o�mH�s2��)�=��2�.�l����jg�9$�Y�S�%*L������R�Y������7Z���,*=�䷘$�������arm�o�ϰ���UW.|�r�uf����IGw�t����Zwo��~5 ��YյhO+=8fF�)�W�7�L9lM�̘·Y���֘YLf�큹�pRF���99.A �"wz��=E\Z���'a� 2��Ǚ�#;�'}�G���*��l��^"q��+2FQ� hj��kŦ��${���ޮ-�T�٭cf�|�3#~�RJ����t��$b�(R��(����r���dx� >U b�&9,>���%E\� Ά�e�$��'�q't��*�א���ެ�b��-|d���SB�O�O��$�R+�H�)�܎�K��1m`;�J�2�Y~9��O�g8=vqD`K[�F)k�[���1m޼c��n���]s�k�z$@��)!I �x՝"v��9=�ZA=`Ɠi �:�E��)`7��vI��}d�YI�_ �o�:ob���o ���3Q��&D&�2=�� �Ά��;>�h����y.*ⅥS������Ӭ�+q&����j|UƧ����}���J0��WW< ۋS�)jQR�j���Ư��rN)�Gű�4Ѷ(�S)Ǣ�8��i��W52���No˓� ۍ%�5brOn�L�;�n��\G����=�^U�dI���8$�&���h��'���+�(������cȁ߫k�l��S^���cƗjԌE�ꭔ��gF���Ȓ��@���}O���*;e�v�WV���YJ\�]X'5��ղ�k�F��b 6R�o՜m��i N�i����>J����?��lPm�U��}>_Z&�KK��q�r��I�D�Չ~�q�3fL�:S�e>���E���-G���{L�6p�e,8��������QI��h��a�Xa��U�A'���ʂ���s�+טIjP�-��y�8ۈZ?J$��W�P� ��R�s�]��|�l(�ԓ��sƊi��o(��S0��Y� 8�T97.�����WiL��c�~�dxc�E|�2!�X�K�Ƙਫ਼�$((�6�~|d9u+�qd�^3�89��Y�6L�.I�����?���iI�q���9�)O/뚅����O���X��X�V��ZF[�یgQ�L��K1���RҖr@v�#��X�l��F���Нy�S�8�7�kF!A��sM���^rkp�jP�DyS$N���q��nxҍ!U�f�!eh�i�2�m���`�Y�I�9r�6� �TF���C}/�y�^���Η���5d�'��9A-��J��>{�_l+�`��A���[�'��յ�ϛ#w:݅�%��X�}�&�PSt�Q�"�-��\縵�/����$Ɨh�Xb�*�y��BS����;W�ջ_mc�����vt?2}1�;qS�d�d~u:2k5�2�R�~�z+|HE!)�Ǟl��7`��0�<�,�2*���Hl-��x�^����'_TV�gZA�'j� ^�2Ϊ��N7t�����?w�� �x1��f��Iz�C-Ȗ��K�^q�;���-W�DvT�7��8�Z�������� hK�(P:��Q- �8�n�Z���܃e貾�<�1�YT<�,�����"�6{/ �?�͟��|1�:�#g��W�>$����d��J��d�B��=��jf[��%rE^��il:��B���x���Sּ�1հ��,�=��*�7 fcG��#q� �eh?��2�7�����,�!7x��6�n�LC�4x��},Geǝ�tC.��vS �F�43��zz\��;QYC,6����~;RYS/6���|2���5���v��T��i����������mlv��������&� �nRh^ejR�LG�f���? �ۉҬܦƩ��|��Ȱ����>3����!v��i�ʯ�>�v��オ�X3e���_1z�Kȗ\<������!�8���V��]��?b�k41�Re��T�q��mz��TiOʦ�Z��Xq���L������q"+���2ۨ��8}�&N7XU7Ap�d�X��~�׿��&4e�o�F��� �H����O���č�c�� 懴�6���͉��+)��v;j��ݷ�� �UV�� i��� j���Y9GdÒJ1��詞�����V?h��l����l�cGs�ځ�������y�Ac�����\V3�? �� ܙg�>qH�S,�E�W�[�㺨�uch�⍸�O�}���a��>�q�6�n6����N6�q������N ! 1AQaq�0@����"2BRb�#Pr���3C`��Scst���$4D���%Td�� ?���N����a��3��m���C���w��������xA�m�q�m���m������$����4n淿t'��C"w��zU=D�\R+w�p+Y�T�&�պ@��ƃ��3ޯ?�Aﶂ��aŘ���@-�����Q�=���9D��ռ�ѻ@��M�V��P��܅�G5�f�Y<�u=,EC)�<�Fy'�"�&�չ�X~f��l�KԆV��?�� �W�N����=(� �;���{�r����ٌ�Y���h{�١������jW����P���Tc�����X�K�r��}���w�R��%��?���E��m�� �Y�q|����\lEE4���r���}�lsI�Y������f�$�=�d�yO����p�����yBj8jU�o�/�S��?�U��*������ˍ�0������u�q�m [�?f����a�� )Q�>����6#������� ?����0UQ����,IX���(6ڵ[�DI�MNލ�c&���υ�j\��X�R|,4��� j������T�hA�e��^���d���b<����n�� �즇�=!���3�^�`j�h�ȓr��jẕ�c�,ٞX����-����a�ﶔ���#�$��]w�O��Ӫ�1y%��L�Y<�wg#�ǝ�̗`�x�xa�t�w��»1���o7o5��>�m뭛C���Uƃߜ}�C���y1Xνm�F8�jI���]����H���ۺиE@I�i;r�8ӭ����V�F�Շ| ��&?�3|x�B�MuS�Ge�=Ӕ�#BE5G�����Y!z��_e��q�р/W>|-�Ci߇�t�1ޯќd�R3�u��g�=0 5��[?�#͏��q�cf���H��{ ?u�=?�?ǯ���}Z��z���hmΔ�BFTW�����<�q�(v� ��!��z���iW]*�J�V�z��gX֧A�q�&��/w���u�gYӘa���; �i=����g:��?2�dž6�ى�k�4�>�Pxs����}������G�9��3 ���)gG�R<>r h�$��'nc�h�P��Bj��J�ҧH� -��N1���N��?��~��}-q!=��_2hc�M��l�vY%UE�@|�v����M2�.Y[|y�"Eï��K�ZF,�ɯ?,q�?v�M 80jx�"�;�9vk�����+ ֧�� �ȺU��?�%�vcV��mA�6��Qg^M����A}�3�nl� QRN�l8�kkn�'�����(��M�7m9و�q���%ޟ���*h$Zk"��$�9��: �?U8�Sl��,,|ɒ��xH(ѷ����Gn�/Q�4�P��G�%��Ա8�N��!� �&�7�;���eKM7�4��9R/%����l�c>�x;������>��C�:�����t��h?aKX�bhe�ᜋ^�$�Iհ �hr7%F$�E��Fd���t��5���+�(M6�t����Ü�UU|zW�=a�Ts�Tg������dqP�Q����b'�m���1{|Y����X�N��b �P~��F^F:����k6�"�j!�� �I�r�`��1&�-$�Bevk:y���#yw��I0��x��=D�4��tU���P�ZH��ڠ底taP��6����b>�xa����Q�#� WeF��ŮNj�p�J* mQ�N����*I�-*�ȩ�F�g�3 �5��V�ʊ�ɮ�a��5F���O@{���NX��?����H�]3��1�Ri_u��������ѕ�� ����0��� F��~��:60�p�͈�S��qX#a�5>���`�o&+�<2�D����: �������ڝ�$�nP���*)�N�|y�Ej�F�5ټ�e���ihy�Z �>���k�bH�a�v��h�-#���!�Po=@k̆IEN��@��}Ll?j�O������߭�ʞ���Q|A07x���wt!xf���I2?Z��<ץ�T���cU�j��]��陎Ltl �}5�ϓ��$�,��O�mˊ�;�@O��jE��j(�ا,��LX���LO���Ц�90�O �.����a��nA���7������j4 ��W��_ٓ���zW�jcB������y՗+EM�)d���N�g6�y1_x��p�$Lv:��9�"z��p���ʙ$��^��JԼ*�ϭ����o���=x�Lj�6�J��u82�A�H�3$�ٕ@�=Vv�]�'�qEz�;I˼��)��=��ɯ���x �/�W(V���p�����$ �m�������u�����񶤑Oqˎ�T����r��㠚x�sr�GC��byp�G��1ߠ�w e�8�$⿄����/�M{*}��W�]˷.�CK\�ުx���/$�WPw���r� |i���&�}�{�X� �>��$-��l���?-z���g����lΆ���(F���h�vS*���b���߲ڡn,|)mrH[���a�3�ר�[1��3o_�U�3�TC�$��(�=�)0�kgP���� ��u�^=��4 �WYCҸ:��vQ�ר�X�à��tk�m,�t*��^�,�}D*� �"(�I��9R����>`�`��[~Q]�#af��i6l��8���6�:,s�s�N6�j"�A4���IuQ��6E,�GnH��zS�HO�uk�5$�I�4��ؤ�Q9�@��C����wp�BGv[]�u�Ov���0I4���\��y�����Q�Ѹ��~>Z��8�T��a��q�ޣ;z��a���/��S��I:�ܫ_�|������>=Z����8:�S��U�I�J��"IY���8%b8���H��:�QO�6�;7�I�S��J��ҌAά3��>c���E+&jf$eC+�z�;��V����� �r���ʺ������my�e���aQ�f&��6�ND��.:��NT�vm�<- u���ǝ\MvZY�N�NT��-A�>jr!S��n�O 1�3�Ns�%�3D@���`������ܟ 1�^c<���� �a�ɽ�̲�Xë#�w�|y�cW�=�9I*H8�p�^(4���՗�k��arOcW�tO�\�ƍR��8����'�K���I�Q�����?5�>[�}��yU�ײ -h��=��% q�ThG�2�)���"ו3]�!kB��*p�FDl�A���,�eEi�H�f�Ps�����5�H:�Փ~�H�0Dت�D�I����h�F3�������c��2���E��9�H��5�zԑ�ʚ�i�X�=:m�xg�hd(�v����׊�9iS��O��d@0ڽ���:�p�5�h-��t�&���X�q�ӕ,��ie�|���7A�2���O%P��E��htj��Y1��w�Ѓ!����  ���� ࢽ��My�7�\�a�@�ţ�J �4�Ȼ�F�@o�̒?4�wx��)��]�P��~�����u�����5�����7X ��9��^ܩ�U;Iꭆ 5 �������eK2�7(�{|��Y׎ �V��\"���Z�1� Z�����}��(�Ǝ"�1S���_�vE30>���p;� ΝD��%x�W�?W?v����o�^V�i�d��r[��/&>�~`�9Wh��y�;���R��� ;;ɮT��?����r$�g1�K����A��C��c��K��l:�'��3 c�ﳯ*"t8�~l��)���m��+U,z��`(�>yJ�?����h>��]��v��ЍG*�{`��;y]��I�T� ;c��NU�fo¾h���/$���|NS���1�S�"�H��V���T���4��uhǜ�]�v;���5�͠x��'C\�SBpl���h}�N����� A�Bx���%��ޭ�l��/����T��w�ʽ]D�=����K���ž�r㻠l4�S�O?=�k �M:� ��c�C�a�#ha���)�ѐxc�s���gP�iG��{+���x���Q���I= �� z��ԫ+ �8"�k�ñ�j=|����c ��y��CF��/��*9ж�h{ �?4�o� ��k�m�Q�N�x��;�Y��4膚�a�w?�6�>e]�����Q�r�:����g�,i"�����ԩA�*M�<�G��b�if��l^M��5� �Ҩ�{����6J��ZJ�����P�*�����Y���ݛu�_4�9�I8�7���������,^ToR���m4�H��?�N�S�ѕw��/S��甍�@�9H�S�T��t�ƻ���ʒU��*{Xs�@����f�����֒Li�K{H�w^���������Ϥm�tq���s� ���ք��f:��o~s��g�r��ט� �S�ѱC�e]�x���a��) ���(b-$(�j>�7q�B?ӕ�F��hV25r[7 Y� }L�R��}����*sg+��x�r�2�U=�*'WS��ZDW]�WǞ�<��叓���{�$�9Ou4��y�90-�1�'*D`�c�^o?(�9��u���ݐ��'PI&� f�Jݮ�������:wS����jfP1F:X �H�9dԯ���˝[�_54 �}*;@�ܨ�� ð�yn�T���?�ןd�#���4rG�ͨ��H�1�|-#���Mr�S3��G�3�����)�.᧏3v�z֑��r����$G"�`j �1t��x0<Ɔ�Wh6�y�6��,œ�Ga��gA����y��b��)��h�D��ß�_�m��ü �gG;��e�v��ݝ�nQ� ��C����-�*��o���y�a��M��I�>�<���]obD��"�:���G�A��-\%LT�8���c�)��+y76���o�Q�#*{�(F�⽕�y����=���rW�\p���۩�c���A���^e6��K������ʐ�cVf5$�'->���ՉN"���F�"�UQ@�f��Gb~��#�&�M=��8�ט�JNu9��D��[̤�s�o�~������ G��9T�tW^g5y$b��Y'��س�Ǵ�=��U-2 #�MC�t(�i� �lj�@Q 5�̣i�*�O����s�x�K�f��}\��M{E�V�{�υ��Ƈ�����);�H����I��fe�Lȣr�2��>��W�I�Ȃ6������i��k�� �5�YOxȺ����>��Y�f5'��|��H+��98pj�n�.O�y�������jY��~��i�w'������l�;�s�2��Y��:'lg�ꥴ)o#'Sa�a�K��Z� �m��}�`169�n���"���x��I ��*+� }F<��cГ���F�P�������ֹ*�PqX�x۩��,� ��N�� �4<-����%����:��7����W���u�`����� $�?�I��&����o��o��`v�>��P��"��l���4��5'�Z�gE���8���?��[�X�7(��.Q�-��*���ތL@̲����v��.5���[��=�t\+�CNܛ��,g�SQnH����}*F�G16���&:�t��4ُ"A��̣��$�b �|����#rs��a�����T�� ]�<�j��BS�('$�ɻ� �wP;�/�n��?�ݜ��x�F��yUn�~mL*-�������Xf�wd^�a�}��f�,=t�׵i�.2/wpN�Ep8�OР���•��R�FJ� 55TZ��T �ɭ�<��]��/�0�r�@�f��V��V����Nz�G��^���7hZi����k��3�,kN�e|�vg�1{9]_i��X5y7� 8e]�U����'�-2,���e"����]ot�I��Y_��n�(JҼ��1�O ]bXc���Nu�No��pS���Q_���_�?i�~�x h5d'�(qw52] ��'ޤ�q��o1�R!���`ywy�A4u���h<קy���\[~�4�\ X�Wt/� 6�����n�F�a8��f���z �3$�t(���q��q�x��^�XWeN'p<-v�!�{�(>ӽDP7��ո0�y)�e$ٕv�Ih'Q�EA�m*�H��RI��=:��� ���4牢) �%_iN�ݧ�l]� �Nt���G��H�L��� ɱ�g<���1V�,�J~�ٹ�"K��Q�� 9�HS�9�?@��k����r�;we݁�]I�!{ �@�G�[�"��`���J:�n]�{�cA�E����V��ʆ���#��U9�6����j�#Y�m\��q�e4h�B�7��C�������d<�?J����1g:ٳ���=Y���D�p�ц� ׈ǔ��1�]26؜oS�'��9�V�FVu�P�h�9�xc�oq�X��p�o�5��Ա5$�9W�V(�[Ak�aY錎qf;�'�[�|���b�6�Ck��)��#a#a˙��8���=äh�4��2��C��4tm^ �n'c���]GQ$[Wҿ��i���vN�{Fu ��1�gx��1┷���N�m��{j-,��x�� Ūm�ЧS�[�s���Gna���䑴�� x�p 8<������97�Q���ϴ�v�aϚG��Rt�Һ׈�f^\r��WH�JU�7Z���y)�vg=����n��4�_)y��D'y�6�]�c�5̪�\� �PF�k����&�c;��cq�$~T�7j ���nç]�<�g ":�to�t}�159�<�/�8������m�b�K#g'I'.W�����6��I/��>v��\�MN��g���m�A�yQL�4u�Lj�j9��#44�t��l^�}L����n��R��!��t��±]��r��h6ٍ>�yҏ�N��fU�� ���� Fm@�8}�/u��jb9������he:A�y�ծw��GpΧh�5����l}�3p468��)U��d��c����;Us/�֔�YX�1�O2��uq�s��`hwg�r~�{ R��mhN��؎*q 42�*th��>�#���E����#��Hv�O����q�}�����6�e��\�,Wk�#���X��b>��p}�դ��3���T5��†��6��[��@�P�y*n��|'f�֧>�lư΂�̺����SU�'*�q�p�_S�����M�� '��c�6�����m�� ySʨ;M��r���Ƌ�m�Kxo,���Gm�P��A�G�:��i��w�9�}M(�^�V��$ǒ�ѽ�9���|���� �a����J�SQ�a���r�B;����}���ٻ֢�2�%U���c�#�g���N�a�ݕ�'�v�[�OY'��3L�3�;,p�]@�S��{ls��X�'���c�jw�k'a�.��}�}&�� �dP�*�bK=ɍ!����;3n�gΊU�ߴmt�'*{,=SzfD� A��ko~�G�aoq�_mi}#�m�������P�Xhύ����mxǍ�΂���巿zf��Q���c���|kc�����?���W��Y�$���_Lv����l߶��c���`?����l�j�ݲˏ!V��6����U�Ђ(A���4y)H���p�Z_�x��>���e��R��$�/�`^'3qˏ�-&Q�=?��CFVR �D�fV�9��{�8g�������n�h�(P"��6�[�D���< E�����~0<@�`�G�6����Hг�cc�� �c�K.5��D��d�B���`?�XQ��2��ٿyqo&+�1^� DW�0�ꊩ���G�#��Q�nL3��c���������/��x ��1�1[y�x�პCW��C�c�UĨ80�m�e�4.{�m��u���I=��f�����0QRls9���f���������9���~f�����Ǩ��a�"@�8���ȁ�Q����#c�ic������G��$���G���r/$W�(��W���V�"��m�7�[m�A�m����bo��D� j����۳� l���^�k�h׽����� ��#� iXn�v��eT�k�a�^Y�4�BN��ĕ��0 !01@Q"2AaPq3BR������?���@4�Q�����T3,���㺠�W�[=JK�Ϟ���2�r^7��vc�:�9 �E�ߴ�w�S#d���Ix��u��:��Hp��9E!�� V 2;73|F��9Y���*ʬ�F��D����u&���y؟��^EA��A��(ɩ���^��GV:ݜDy�`��Jr29ܾ�㝉��[���E;Fzx��YG��U�e�Y�C���� ����v-tx����I�sם�Ę�q��Eb�+P\ :>�i�C'�;�����k|z�رn�y]�#ǿb��Q��������w�����(�r|ӹs��[�D��2v-%��@;�8<a���[\o[ϧw��I!��*0�krs)�[�J9^��ʜ��p1)� "��/_>��o��<1����A�E�y^�C��`�x1'ܣn�p��s`l���fQ��):�l����b>�Me�jH^?�kl3(�z:���1ŠK&?Q�~�{�ٺ�h�y���/�[��V�|6��}�KbX����mn[-��7�5q�94�������dm���c^���h� X��5��<�eޘ>G���-�}�دB�ޟ� ��|�rt�M��V+�]�c?�-#ڛ��^ǂ}���Lkr���O��u�>�-D�ry� D?:ޞ�U��ǜ�7�V��?瓮�"�#���r��չģVR;�n���/_� ؉v�ݶe5d�b9��/O��009�G���5n�W����JpA�*�r9�>�1��.[t���s�F���nQ� V 77R�]�ɫ8����_0<՜�IF�u(v��4��F�k�3��E)��N:��yڮe��P�`�1}�$WS��J�SQ�N�j�ٺ��޵�#l���ј(�5=��5�lǏmoW�v-�1����v,W�mn��߀$x�<����v�j(����c]��@#��1������Ǔ���o'��u+����;G�#�޸��v-lη��/(`i⣍Pm^���ԯ̾9Z��F��������n��1��� ��]�[��)�'������:�֪�W��FC����� �B9،!?���]��V��A�Վ�M��b�w��G F>_DȬ0¤�#�QR�[V��kz���m�w�"��9ZG�7'[��=�Q����j8R?�zf�\a�=��O�U����*oB�A�|G���2�54 �p��.w7� �� ��&������ξxGHp� B%��$g�����t�Џ򤵍z���HN�u�Я�-�'4��0��;_��3 !01"@AQa2Pq#3BR������?��ʩca��en��^��8���<�u#��m*08r��y�N"�<�Ѳ0��@\�p��� �����Kv�D��J8�Fҽ� �f�Y��-m�ybX�NP����}�!*8t(�OqѢ��Q�wW�K��ZD��Δ^e��!� ��B�K��p~�����e*l}z#9ң�k���q#�Ft�o��S�R����-�w�!�S���Ӥß|M�l޶V��!eˈ�8Y���c�ЮM2��tk���� ������J�fS����Ö*i/2�����n]�k�\���|4yX�8��U�P.���Ы[���l��@"�t�<������5�lF���vU�����W��W��;�b�cД^6[#7@vU�xgZv��F�6��Q,K�v��� �+Ъ��n��Ǣ��Ft���8��0��c�@�!�Zq s�v�t�;#](B��-�nῃ~���3g������5�J�%���O������n�kB�ĺ�.r��+���#�N$?�q�/�s�6��p��a����a��J/��M�8��6�ܰ"�*������ɗud"\w���aT(����[��F��U՛����RT�b���n�*��6���O��SJ�.�ij<�v�MT��R\c��5l�sZB>F��<7�;EA��{��E���Ö��1U/�#��d1�a�n.1ě����0�ʾR�h��|�R��Ao�3�m3 ��%�� ���28Q� ��y��φ���H�To�7�lW>����#i`�q���c����a��� �m,B�-j����݋�'mR1Ήt�>��V��p���s�0IbI�C.���1R�ea�����]H�6����������4B>��o��](��$B���m�����a�!=��?�B� K�Ǿ+�Ծ"�n���K��*��+��[T#�{E�J�S����Q�����s�5�:�U�\wĐ�f�3����܆&�)����I���Ԇw��E T�lrTf6Q|R�h:��[K�� �z��c֧�G�C��%\��_�a�84��HcO�bi��ؖV��7H �)*ģK~Xhչ0��4?�0��� �E<���}3���#���u�?�� ��|g�S�6ꊤ�|�I#Hڛ� �ա��w�X��9��7���Ŀ%�SL��y6č��|�F�a 8���b��$�sק�h���b9RAu7�˨p�Č�_\*w��묦��F ����4D~�f����|(�"m���NK��i�S�>�$d7SlA��/�²����SL��|6N�}���S�˯���g��]6��; �#�.��<���q'Q�1|KQ$�����񛩶"�$r�b:���N8�w@��8$�� �AjfG|~�9F ���Y��ʺ��Bwؒ������M:I岎�G��`s�YV5����6��A �b:�W���G�q%l�����F��H���7�������Fsv7��k�� 403WebShell
403Webshell
Server IP : 172.67.215.126  /  Your IP : 172.69.130.92
Web Server : Apache/2.4.52 (Ubuntu)
System : Linux ip-172-31-19-221 6.8.0-1029-aws #31~22.04.1-Ubuntu SMP Thu Apr 24 21:16:18 UTC 2025 x86_64
User : www-data ( 33)
PHP Version : 8.1.28
Disable Function : NONE
MySQL : OFF  |  cURL : ON  |  WGET : ON  |  Perl : ON  |  Python : OFF  |  Sudo : ON  |  Pkexec : ON
Directory :  /efsdata/authorproof.omicsgroup.co.in/paper-submissions-new/2019/Sep/26/

Upload File :
current_dir [ Writeable ] document_root [ Writeable ]

 

Command :


[ Back ]     

Current File : /efsdata/authorproof.omicsgroup.co.in/paper-submissions-new/2019/Sep/26/101114-Source file.doc
��ࡱ�>��	rt����q�������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������U	���`bjbj�n�n	7j��a��ak3&�������

|||||�������8�L$�>=�8:r(���u��<<<<<<<$*@��B;<�|�uu��;<||����<�#�#�#�|�|�<�#�<�#�#�q9�;�����p��_]t������ �):$<=0>=M:��C�!B�C0;;P�C|i;����#�����;<;<�"����>=�������������������������������������������������������������������������C���������
BB:	IL-1 INHIBITORS: WHAT IS THEIR RIGHT POSITION AS THERAPEUTIC OPPORTUNITY?
Piercarlo Sarzi-Puttini, MD1, Daniela Marotto, MD2

1Rheumatology Unit, ASST Fatebenefratelli-Sacco, University of Milan, Italy.  HYPERLINK "mailto:piercarlo.sarziputtini@gmail.com"piercarlo.sarziputtini@gmail.com
2Rheumatology Unit, P-Dettori Hospital  Tempio Pausania, Italy, daniela.marotto@tiscali.it


Ever since the first description of interleukin-1 (IL-1), there has been great interest in understanding how it and its related cytokines play such a key role in inflammatory responses. The large IL-1 family has 11 members with anti-inflammatory activity: seven pro-inflammatory agonists (IL-1�, IL-1�, IL-18, IL-33, and IL-36�, � and �) and four antagonists (IL-1 receptor [IL-1R] antagonist [IL-1RA], IL- 36RA, IL-37, and IL-38), of which IL-1� and IL-1� are the most widely studied.
The IL-1 family plays a key pathogenic role in auto-inflammatory, auto-immune, infectious, degenerative and malignant diseases, and the subsequently acquired knowledge has led to the development of specific strategies for inhibiting some of its members. Nevertheless, it is surprising how much more has been discovered about its role inflammatory processes over the last 20 years [1-4]. 
It is now known that many auto-inflammatory and auto-immune diseases are characterised by a multifaceted network of dynamic interactions between innate and adaptive immunity, although the boundary between these two characteristics is becoming blurred as a result of the increasing number of diseases reported to be characterised by both. The crucial role of the multifunctional IL-1 family has understandably increased interest in the possibility of targeting these cytokines in the treatment of a wide range of auto-inflammatory diseases, including rheumatoid arthritis (RA), gout, cardiometabolic diseases (including type 2 diabetes [T2D], atherosclerosis and malignancies [5,6], the natural course of many of which has been radically changed by blocking or reducing IL-1 activity [7-10].
Only two of the four currently available IL-1 inhibitors have been approved for use in Europe: the receptor antagonist anakinra (ANA) and the selective IL-1( inhibitor canakinumab (CAN).  
ANA binding the IL 1 receptor type I  inhibit both the IL-1 subunits a and (.
After it had been proved to be capable of reducing joint destruction, ANA was approved in 2001 for the treatment of moderate-severe RA in association with methotrexate. However, it is only infrequently used in patients with early and established RA because it is less efficacious than the currently dominant TNF inhibitors and other biological agents [11-13]. ANA has also been found to be effective in many other joint and muscular diseases, and its other currently approved indications are cryopyrin-associated periodic syndromes (CAPS) and adult-onset Still�s disease (AOSD)[14].
Several clinical trials about its efficacy on decreasing cardiovascular risk and cardiovascular events have also been developed after that animal experiments have confirmed its cardiovascular effectiveness [15].
Five clinical trials have shown that the most frequent ANA-related adverse events are injection site reactions, infections (at doses of >100�mg), and immunogenicity. Furthermore, as it has a short half-life of 4-6 hours, ANA must be injected every day and is therefore often poorly tolerated.
CAN is a human monoclonal antibody with a high affinity for human IL-1�, is mainly eliminated by means of intracellular catabolism, and has a half-life of 26 days. Its binding to circulating IL-1� blocks the interaction between IL-1�  to its receptor neutralizing its activity. Its high affinity and specificity for IL-1� makes it very suitable for various therapeutic purposes [16,17], and its bi-weekly administration gives it a great advantage over ANA. Originally approved for the treatment of CAPS in 2009, its rapidly increasing indications now include tumour necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulinemia D syndrome/mevalonate kinase deficiency (HIDS/MKD), familial Mediterranean fever (FMF), gout, systemic juvenile idiopatic arthritis (SJIA), and AOSD, in all of which it leads to a rapid and sustained improvement in symptoms, a complete clinical response, and a reduction in inflammatory markers (serum C-reactive protein and amyloid-A). It also has a good safety profile. Long-term remission has been observed in patients with SJIA. 
There is ample evidence showing that anti-IL-1 agents have a strong steroid-sparing effect, and lead to a reduction or discontinuation of disease-modifying anti-rheumatic drugs, accompanied by a significant decrease in the side effects of co-treatments[18]. These effects have been confirmed in patients with AOSD, in whom high response rates have been consistently reported (especially in refractory cases), with complete or partial remissions in most, a reduction or discontinuation of steroids, and decreased co-treatment side effects. However, joint symptoms are less well controlled than systemic symptoms, and can take longer to respond to treatment. The efficacy of anti-IL-1 agents suggests that early treatment can avoid serious disease- or co-treatment-related complications , and new findings continue to reveal novel indications [19].
Recent extensive research has demonstrated that IL-1 may be at the centre of hypotheses linking inflammation with the pathogenesis of atherosclerosis, and may be involved in pathological cardiac events after a myocardial infarction, including the inflammation and remodelling that weaken heart muscle tissue and contribute to subsequent heart failure [20]. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) confirmed that IL-1 (particularly IL-1()-related inflammation is an independent risk factor for cardiovascular events [20]. The primary endpoint of the CANTOS was the incidence of adverse cardiac events (cardiovascular death, myocardial infarction, or stroke), and the results showed that CAN was superior to placebo in preventing them. 
It has been found that IL-1� and IL-1� are over-expressed in patients with advanced neoplasms, and that this was associated with higher tumour grades and greater invasiveness [21]. Pre-clinical studies of ANA have reported inhibited colon tumour growth, a significant survival benefit, and improved quality of life scores when it is added to standard-of-care chemotherapy in patients with metastatic colorectal cancer [22], and one unexpected finding of CANTOS was a significantly lower incidence of lung cancer and deaths due to all cancers in CAN-treated patients [23]. This latter finding inspired several trials such as one of combination with canakinumab and a programmed cell death protein 1 (PD-1) inhibitor in patients with   non-small cell lung cancer [24,25]. However, further studies are required to clarify the possible role of IL-1 inhibition in the treatment of cancer.
Anti-IL-1 therapy may have a beneficial effect on T2D as it has been found that it improves insulin production and glycemic control, and decreases C-reactive protein (CRP) and IL-6 levels [26]. Its possible protective role in type 1 diabetes has also been evaluated. 
Other studies have tested CAN and ANA in patients with chronic obstructive pulmonary disease, sarcoidosis, Beh�et�s disease, pyoderma gangrenosum, Schnitzler�s syndrome and urticarial vasculitis with encouraging results, and it is likely that the indications for CAN will be further extended.
A number of  HYPERLINK "https://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/biochemistry-genetics-and-molecular-biology/gene-mutation"genetic modifications and mutations associated with dysregulated IL-1 activity and auto-inflammatory manifestations have been identified in humans and animal models, and IL-1 inhibitors have been found to be effective in diseases that were previously considered untreatable. The identification of� HYPERLINK "https://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/medicine-and-dentistry/autoinflammatory-disease"auto-inflammatory disorders�associated with increased levels of other cytokines in the IL-1 family should also permit the development of specific anti-cytokine therapies.
REFERENCES
Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013 Dec 12;39(6):1003-18.  
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27:519�550. 
Dinarello CA. Anti-inflammatory Agents: Present and Future. Cell. 2010; 140:935�950. 
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117:3720�3732. 
Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Rev Drug Discov. 2012; 11:633�652.
Hong DS, N A, Falchook GS, Piha-PAul S, Wheler JJ, Fu S, Tsimberidou AM, Hui D, Scott R, K R, et al. A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. Mol Cancer Ther. 2011; 10:A211.
Larsen CM, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007; 356:1517�1526. 
Abbate A, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. Am J Cardiol. 2010; 105:1371�1377. 
Van Tassell BW, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS ONE. 2012;7
Goldbach-Mansky R, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1� inhibition. N Engl J Med. 2006; 355:581 592.
Scott IC, Ibrahim F, Simpson G, Kowalczyk A, White-Alao B, Hassell A, Plant M,Richards S, Walker D, Scott DL. A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):88-93.
Mertens M, Singh  JA: Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36: 1118-25. 
Rondeau, J. M., Ramage, P., Zurini, M., and Gram, H. (2015). The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1�. MAbs 7, 1151 1160. 
Sota J, Rigante D, Ruscitti P, Insalaco A, Sfriso P, de Vita S, Cimaz R, Lopalco G, Emmi G et al. Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Front Pharmacol. 2019 Aug 23;10:918.
Zheng ZH, Zeng X, Nie XY, Cheng YJ, Liu J, Lin XX, Yao H, Ji CC, Chen XM, Jun F, Wu SH.
Interleukin-1 blockade treatment decreasing cardiovascular risk. Clin Cardiol. 2019 Aug 15. doi: 10.1002/clc.2324
$Jefh{}~��			"	#	%	�������Ƕ��v�[vFv2'h4Nh��B*H*OJPJQJ\�ph)h4Nh��0JB*OJQJmHphsH4�jh4Nh��B*OJQJUmH	phsH	.jh4Nh��B*OJQJUmH	phsH	%h4Nh��B*OJQJmH	phsH	(h4Nh��B*H*OJQJmH	phsH	 h4Nh��B*H*OJQJphh4Nh��B*H*^Jphh4Nh��5�B*^Jphh4Nh*I�B*^Jphh4Nh��B*^JphJ}~$		�	�	��~
T(���!�%J)V*{+].i.�.������������������������$
&F	dha$gd�Ud�	$d�1$a$d�$d�a$d�gd�U%	~	�	<>z|~������

�N��̶̣���j�j�j�T�?�)h4Nh��B*OJPJQJmH	phsH	+	jb�h4Nh�?B*OJQJmH	phsH	(h4Nh�?B*OJQJmH	o(phsH	 h4Nh�?B*mH	o(phsH	%h4Nh�?B*OJQJmH	phsH	%h4Nh�A#B*OJQJmH	phsH	+	jb�h4Nh��B*OJQJmH	phsH	%h4Nh��B*OJQJmH	phsH	h4Nh��B*OJQJph!h4Nh��B*OJPJQJphNRS�����!$%&(������įįįį���p�[F)h4Nh�,0B*OJQJ^JmH	phsH	)h4Nh��B*OJQJ^JmH	phsH	)h4Nh��B*OJPJQJmH	phsH	)h4NhZ�B*OJPJQJmH	phsH	)h4Nh,
�B*OJPJQJmH	phsH	)h4Nh�(�B*OJPJQJmH	phsH	)h4Nh�?B*OJPJQJmH	phsH	%h4Nh��B*OJQJmH	phsH	%h4Nh,
�B*OJQJmH	phsH	� "0<Pjl~��z�����}���䲛�䲆s`M:`s%h4NhOFB*OJQJmH	phsH	%h4Nh�8�B*OJQJmH	phsH	%h4NhF�B*OJQJmH	phsH	%h4Nh��B*OJQJmH	phsH	)h4Nh��B*OJQJ^JmH	phsH	-h4Nh�,0B*OJPJQJ^JnHphtH5h4Nh�,0B*OJPJQJ^JmH	nHphsH	tH-h4Nh-a_B*OJPJQJ^JnHphtH5h4Nh-a_B*OJPJQJ^JmH	nHphsH	tH}�������  ^ p �!�!;#=#�#�#�#�#�&�&z'{'((.(6(7(=(>(C(F(X(Y(i(j(n(�(�(�(�(�����ױ������ממ׈ממממ�u�u�u�u�u�u�uמ%h4Nh*I�B*OJQJmH	phsH	+	jb�h4Nh��B*OJQJmH	phsH	%h4NhF�B*OJQJmH	phsH	%h4NhxFB*OJQJmH	phsH	%h4NhOFB*OJQJmH	phsH	%h4Nh��B*OJQJmH	phsH	)h4Nh��B*OJPJQJmH	phsH	+�(�(�(**	*
*�+�+
,,,/,0,6-7-�-�-�-�-�-].i.��Ƴٳƛƀ�i�ƛ�N�i��?h4Nh��B*mH	phsH	4�jh4Nh��B*OJQJUmH	phsH	,h4Nh��0J>*B*OJQJmH	phsH	4�j�h4Nh��B*OJQJUmH	phsH	.jh4Nh��B*OJQJUmH	phsH	%h4Nh4JCB*OJQJmH	phsH	%h4Nh��B*OJQJmH	phsH	%h4NhF�B*OJQJmH	phsH	%h4Nh,
�B*OJQJmH	phsH	�.^/�/)0�0�1K2�2�3(5}6�6h8N:�:;jO�P�R$T�������������������$�8dh1$^�8a$gd�(�$
&F	dh1$a$gd�(�$
&F	dh1$a$gd�U$
&F	dha$gd�U$
&F	dha$gdaUK$
&F	dha$gd�Ui.)0Q0J2K2&5(5�6@8J8h8*9,9(:):N:�:<NjO"P�������whw[JH�;h4NhxFB*^JphU!h4Nh�(�B*^JmH	phsH	h4Nh�(�B*^Jphh4Nh,
�B*mH	phsH	!h4Nh,
�B*^JmH	phsH	h4Nh,
�B*phh4Nh,
�B*^Jph'h4Nh��6�B*]�^JmH	phsH	6h4Nh��B*PJ^JfH�mH	phq�
���sH	!h4Nhj�B*^JmH	phsH	h4Nh��B*^Jph!h4Nh��B*^JmH	phsH	Church, L. D., and McDermott, M. F. (2009). Canakinumab, a fully-human mAb against IL-1�eta for the potential treatment of inflammatory disorders. Curr. Opin. Mol. Ther. 11, 81 89.
Marotto D, De Santis A, Chessa D, Firinu D, Del Giacco S A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout. Rheumatol Ther. 2018 Jun;5(1):303-310
Junge G, Mason J, Feist E Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017 Oct;47(2):295-302.
Marotto, D., Batticciotto, A., Ceribelli, A.,  Sarzi-Puttini, P. (2019). The journey of canakinumab; on- and off-label indications. Beyond Rheumatology, 1(1), 22-30. https://doi.org/10.4081/br.2019.4
Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011 Oct; 162(4):597-605. 
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A. et al., IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003. 100: 2645 2650.
Isambert, N.,Hervieu, A.,Rebe, C.,Hennequin, A.,Borg, C.,Zanetta,S.,Chevriaux, A. et al., Fluorouracil and bevacizumab plus anakinrafor patients with metastatic colorectal cancer refractory to standardtherapies (IRAFU): a single-arm phase 2 study. Oncoimmunology 2018.7:e1474319.
Crossman D, Rothman AMK Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). J Thorac Dis. 2018 Sep;10(Suppl 26).
Chabner, B. A. and Nabel, C. S., Canakinumab and Lung Cancer: Intriguing, but Is It Real? Oncologist 2018. 23: 637 638.
Schenk KM, Reuss JE, Choquette K, Spira AI. A review of canakinumab and its therapeutic potential for non-small cell lung cancer. Anticancer Drugs. 2019 Oct;30(9):879-885
Ruscitti P, Masedu F, Alvaro S, Air� P, Battafarano N, Cantarini L, Cantatore FP, Carlino G, D'Abrosca V, Frassi M, Frediani B, Iacono D et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019 Sep 12;16(9):e1002901.









 PAGE 6

 PAGE 7




"P�P�R�R&S�\�\]
]�]�]^&_(_V`X`�`�`�`�`�`�`�`�`�`�`�`�`�`��̿ݮ������ve�e�]Y]Y]Y]YQMQh��jh��Uh4Njh4NU!h4Nh,
�B*^JmH	phsH	h4Nh,
�B*phh4Nh,
�B*^Jphh4Nh,
�B*mH	phsH	!h4Nh,
�B*^JmH	phsH	!h4NhwGB*^JmH	phsH	h4Nh��B*^Jph!h4Nh�8�B*^JmH	phsH	!h4Nh��B*^JmH	phsH	!h4NhxFB*^JmH	phsH	$T"V�W�Y�[�\^�`�`�`�`�`�`�`�`�`�`�`�`�`�`�`�`����������������������!!�h]�h$d�1$a$gd,
�
&F	d�gd,
�$
&F	d�1$a$gd4JC$
&F	dh1$a$gd�U�`�`�`�`�`�`�`�`�`�`�`�`����������!h4Nh,
�B*^JmH	phsH	h4Njh��Uh��jh��U�*h�(�mHnHu�`�`�$d�1$a$gd,
�50p��1�h;0��. ��A!�n"�n#��$�n%��������D���y������K����y������K�Pmailto:piercarlo.sarziputtini@gmail.com]D���y������K����y������K��https://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/biochemistry-genetics-and-molecular-biology/gene-mutationID���y������K����y������K��https://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/medicine-and-dentistry/autoinflammatory-disease�#s���������666666666vvvvvvvvv6666668666666666666666666666666666�6666666666�666666666666hH66666666666666666666666666666666666666666666666666666666666666666p62����&6FVfv������2(��&6FVfv������&6FVfv������&6FVfv������&6FVfv������&6FVfv������&6FVfv��8X�V~�������� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@�� 0@_HmH	nH	sH	tH	T`�TNormal*$(CJOJPJQJ^J_HaJmHsHtHJ@J	Heading 1$@&5�OJQJ\�mH	sH	DA �DDefault Paragraph FontVi�V
0Table Normal :V�4�4�
la�(k �(
0No ListF�/��FDefault Paragraph Font12��2
ghr-conditionFU`�F	Hyperlink>*B*
_H�mH�phc�sH�tH�F�/�!FUnresolved Mention	B*ph`^\h�/�1hPreformattato HTML CarattereCJOJPJQJ^JaJB��ABapple-converted-space*��Q*	highlightF��aFPi� di pagina Carattere.��q.page number6�/�6ListLabel 1mH	sH	L�LHeader
���x$CJOJPJQJ^J	aJ6B�6	Body Text
��x(/��(List^J	H"�HCaption
�x�x$6CJ]^J	aJ0��0Indice$^J	N�O�NList Paragraph1
&F^��]�`�����HTML Preformatted1>
&F
�2�(�
P�x�4 �#\'�*�.2�5@9CJOJPJQJ^JaJJ�J
Normal (Web)1	 
&FOJQJ^J> @>Footer!
&F
���%$LP"LBody Text 2"d�5�OJQJmH	sH	PK!����[Content_Types].xml���N�0E�H���-J��@%�ǎǢ|�ș$�ز�U��L�TB� l,�3��;�r��Ø��J��B+$�G]��7O٭V��<a���(7��I��R�{�pgL�=��r���8�5v&����uQ�뉑8��C����X=��$␴�?6N�JC������F�B.ʹ'�.�+���Y�T���^e5�5�� ��ð�_�g -�;�����Yl�ݎ��|6^�N��`�?���[��PK!�֧�6_rels/.rels���j�0���}Q��%v/��C/�}�(h"���O�
����=������ ����C?�h�v=��Ʌ��%[xp��{۵_�Pѣ<�1�H�0���O�R�Bd���JE�4b$��q_����6L�R�7`������0̞O��,�En7�Li�b��/�S���e��е�����PK!ky���theme/theme/themeManager.xml�M
� @�}�w��7c�(Eb�ˮ��C�AǠҟ����7��՛K
Y,�
�e�.���|,���H�,l����xɴ��I�sQ}#Ր���� ֵ+�!�,�^�$j=�GW��)�E�+&
8���PK!�@���theme/theme/theme1.xml�Y[��F~/�?�;�I�,�[��6�I���<��ck�#�ьwcB�$O})�҇�ևRh��/�1��G��H�g�q�B
�d
�4�Ιo�9��H�z�QD�#�p��[�Rr�ؘ�Ӗ{o�/4\��e1n���k��~r�G���
1�)����f8�k�DH�i2-�t~#Z��J�b�H�:1����Ʉ��3�.�ݥ���Xp90��@�Ɔ�Ž��<��s�h˅y��x�	ס���rK��-�^-��̈�-��]_�ev������L�����{�v�_����Z���S4�JS.�O���t����C��n�[-x�u�sۗ?�@�o��E�@)��{^�x^�R|m_/��^�+PHI|��.��j�\m�0z�
o�^�^ɜ�PP
yu�)&,�j-BY��R$H��O��8@�$��#�
o�b�a�T)�KU�/�:RA;i֒0�C���G	����9xu5����'O_�<���ٳ���fs+W��
Ou��?}�ϋ/������oө��\ǿ��7��.���U(N�{�������������!�0wn�c�.�`��� ���0DD�h�S�b$g����@�Z �,�6�x?�����a2���f�}�h�%�(ܔsia��}�d���"td�;@����|Kl.�4�P4�1���1���!F\��(a�M��8D�!���VF7HyY�B�����w:��V��G&�
D-䇘a���E6�CQ=�{H�6��E2�q=. �SL��c�m6�X��� 3����Ed"Am>�c:���E3v@�P�~��D�s�	|��w�<�<�xk��l��l5�
�SZ��2O,����Q��� ��������5y��;y=��eE�G�펍|\P��	��M7�$|n]���ɇ��]4��`�U6��G�(��^�����_�W��-���v]mޣ�{�	�t �q�}�Е�}�v���r���i����0�� D3��]�d�3�S��������x:���8}d-���i*��x����qC��Z}���Wl��qyI@�^��6�I�j!Q_� ��s���Z�{aѴ�hH��Tm�jyV`��f����<U!��2Oi���U�|���L�`���U�������ե�v�L$�r3I�Ȩ�C4�Yu���иh�����d(�|PZ+�ƻX\6�`��
4֕���q˭U}(����	<��a4���r���ޟ�D���Q�Y�E�0
��T
""p�P�\��<
4V���+ ,�&�ʇF�n&O&x$�k#2��)(|�֫��`i���A8>v�<����zYpL8�*��x��٪��S&��;EUC�8��eE���<����hgٚ!�ZH�Fx0�
V��M�r��u�6���Ds�3
U�]Ӯb��6���5y��2Ġiz�O�{]r�K�[�'�]����u��4j��j��K��F�ޱ\����$4կ-ݮ�-���`�R��֫�&�}�������`A<��"xNW���	�
�@�IRـ[��n
8r�	i��K~�*~P(5�^��z�B�oWm߯�{~���T�@caT���.}x
E��5��&Z�i�2bQ��/,EE\}�)W��q���Z�߬6;�B����n�Qh�N�[��~7���9R`�]
�Z�Q������J�~�Y�{�J۫�=��$���S��b�U�v���PK!
ѐ��'theme/theme/_rels/themeManager.xml.rels��M
�0���wooӺ�&݈Э���5
6?$Q��
�,.�a��i����c2�1h�:�q��m��@RN��;d�`��o7�g�K(M&$R(.1�r'J��ЊT���8��V�"��AȻ�H�u}��|�$�b{��P����8�g/]�QAsم(����#��L�[������PK-!����[Content_Types].xmlPK-!�֧�60_rels/.relsPK-!ky���theme/theme/themeManager.xmlPK-!�@����theme/theme/theme1.xmlPK-!
ѐ��'�	theme/theme/_rels/themeManager.xml.relsPK]�
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<a:clrMap xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main" bg1="lt1" tx1="dk1" bg2="lt2" tx2="dk2" accent1="accent1" accent2="accent2" accent3="accent3" accent4="accent4" accent5="accent5" accent6="accent6" hlink="hlink" folHlink="folHlink"/>�3j����	%%%(%	N�}�(i."P�`�` !"#$&13�.$T�`�`%24�"�/6���3X��X��X��!(!��!���8�@�����������0�(	�
��B
�S����	?���	OLE_LINK1D�3z�3Te��8~��JS����i q u ~ � � � � 9!=!^!g!�!�!)"Q"�"�"�"�"�"�"##�#�#)$-$�$�$�$�$�$�$r%v%�%�%�%�%7&�&�&''n'�'�' ($(4(�(/)8)N)�)�)�)�)�)**_*b*�*�*�*�*�*�*�*++)+R+\+c+l+m+q+�+�+3,8,o,�,*-0-5-;-?-G-6.=.F.L.R.Y._.i.o.v.|.�.�.�.�.�.�.///// /)/+/2/B/K/z/�/�/�/�/0�0�0�0�0�0111�1�1�1�12�233'313D3H3k3m3n3p3q3s3t3v3w3�3�3�3�3�3IJ|#$~MO5:~���)"Q"�#�#&�&'m'�'j3k3m3n3p3q3s3t3v3w3�3�333333] � 9!�!")"�"�"�#�#K$\$�$�$r%�%�%&�&'N'n' (3())N)�)�)�*�*.).�.�.�/0�12D3j3k3m3n3p3q3s3t3v3w3�3�3�3�3NR$%��������;=����z{��	3(4(�(�())M)�0�0p1�1�1�1�1j3�3	�������������������1��?=����������
G,������������I�Q����������\������������gf����������^+|�T~����������|`<|�
Dj���������������^��`���[ ]������^��`���.�p�L��^�p`�L�..�@����^�@`���...�����^�`���....	���L��^��`�L�
.....	������^��`���......	
������^��`���.......	
�P�L��^�P`�L�........����P���^��`�P���@����@^�@`�������0���^��`�0���`����`^�``����������^��`����������^��`��������^�`������`���^��`�`���0���0^�0`��h
�8���^�8`����h�H.�h
����^�`����h�H.�h
��	�L�^��	`�L��h�H.�h
�����^��`����h�H.�h
�x���^�x`����h�H.�h
�H�L�^�H`�L��h�H.�h
����^�`����h�H.�h
�����^��`����h�H.�h
���L�^��`�L��h�H.h
�����^��`����h�H.�
�����^��`����h�H.�
�p�L�^�p`�L��h�H.�
�@���^�@`����h�H.�
����^�`����h�H.�
���L�^��`�L��h�H.�
�����^��`����h�H.�
�����^��`����h�H.�
�P�L�^�P`�L��h�H.������^��`���[ ]������^��`���.�p�L��^�p`�L�..�@����^�@`���...�����^�`���....	���L��^��`�L�
.....	������^��`���......	
������^��`���.......	
�P�L��^�P`�L�........h
�����^��`���o(�h�H.�h�����^��`���OJQJ^Jo(�h�Ho�h�p���^�p`���OJ
QJ
o(�h�H���h�@���^�@`���OJQJo(�h�H���h����^�`���OJQJ^Jo(�h�Ho�h�����^��`���OJ
QJ
o(�h�H���h�����^��`���OJQJo(�h�H���h�����^��`���OJQJ^Jo(�h�Ho�h�P���^�P`���OJ
QJ
o(�h�H��������^��`���[ ]������^��`���.�p�L��^�p`�L�..�@����^�@`���...�����^�`���....	���L��^��`�L�
.....	������^��`���......	
������^��`���.......	
�P�L��^�P`�L�........h�����^��`���OJQJo(�h�H���h�����^��`���OJQJ^Jo(�h�Ho�h�p���^�p`���OJ
QJ
o(�h�H���h�@���^�@`���OJQJo(�h�H���h����^�`���OJQJ^Jo(�h�Ho�h�����^��`���OJ
QJ
o(�h�H���h�����^��`���OJQJo(�h�H���h�����^��`���OJQJ^Jo(�h�Ho�h�P���^�P`���OJ
QJ
o(�h�H��h
�8���^�8`����h�H.�h
����^�`����h�H.�h
��	�L�^��	`�L��h�H.�h
�����^��`����h�H.�h
�x���^�x`����h�H.�h
�H�L�^�H`�L��h�H.�h
����^�`����h�H.�h
�����^��`����h�H.�h
���L�^��`�L��h�H.	�I�Q�gf�^+|�\��
G|`<|�1���������������������������������������	WWNum1��	�RX�M�/�RX""hg�303jq ��UOFwG@?�-!�A#�,0�Y6�?4JCV}CxFaUK4Ns=R-a_�^ab:eZ;wZ��,��I�]�F�,
����8��(��b��(�*I�j�k3m3�@k3�	
�%�&()*�3�@�
�@��(@���8@�$�L@�4�l@�8�t@�N��Unknown������������G��.�[x�	�Times New Roman5��Symbol3.��.�[x�	�Arial7.��.�{$�	�Calibri3�MS ??;���(SimSun�[SO9�Calibri?=�	�.�Cx�	�Courier NewG.����P<�*Microsoft YaHeiM� MangalCourier New;��WingdingsA���$B�Cambria MathC� �h�y�9�y�ry'��+��]��+]! 0Q3Q3J�Q ��HP	�	$P'���������������������*I�2!xx����NIL-1 drug inhibitors: what is their  right position as therapeutic opportunityDaniela MarottoHarshitha Yarradoddi0	��
��Oh��+'��0����� 0	P\
|��
������PIL-1 drug inhibitors: what is their  right position as therapeutic opportunityDaniela MarottoNormalHarshitha Yarradoddi3Microsoft Office Word@@���a�@��[5t�@�O]t���+��
��՜.��+,��D��՜.��+,����hp��������
�~�Hewlett-Packard Company]Q3OIL-1 drug inhibitors: what is their  right position as therapeutic opportunityOIL-1 drug inhibitors: what is their  right position as therapeutic opportunityTitleTitolo�	P��������_PID_HLINKSAppVersionDocSecurityHyperlinksChangedLinksUpToDate
ScaleCrop	ShareDoc�A�tlhttps://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/medicine-and-dentistry/autoinflammatory-diseasePQvhttps://www-sciencedirect-com.pros.lib.unimi.it:2050/topics/biochemistry-genetics-and-molecular-biology/gene-mutationd(mailto:piercarlo.sarziputtini@gmail.com16.0000	

 !"#$%&'()*+,-./012345����789:;<=����?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`����bcdefgh����jklmnop��������s����������������������������������������������������Root Entry��������	�FP��_]t�u�Data
������������61Table����>DWordDocument����7jSummaryInformation(������������aDocumentSummaryInformation8��������iCompObj������������r������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
����	�F Microsoft Word 97-2003 Document
MSWordDocWord.Document.8�9�q

Youez - 2016 - github.com/yon3zu
LinuXploit